Extracellular RNA Markers of Liver Disease and Cancer

Stopped early

Conditions studied: Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases

In brief

The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery

Key facts

Study ID

NCT02908048

Run by

Mayo Clinic

People needed

1865

Starts

2014-07-01

Expected to finish

2024-04-02

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Lab results from within the previous 90 days.
• Diagnosis of HCC or biliary tract cancer
• Diagnosis of cirrhosis based on histology, imaging, or ultrasound.
• Diagnosis of a chronic liver disease without cirrhosis.
• Exclusion Criteria for the HCC/biliary tract cancer group:
• Prior solid organ transplant.
• Previous cancer history with the last 5 years (excluding non-melanoma skin cancer), participation in a treatment trial for HCC
• Exclusion criteria for the cirrhosis and chronic liver disease groups:
• Prior solid organ transplant.
• Previous or current cancer history within the past 5 years (excluding non-melanoma skin cancer).

Where it is running

• Mayo Clinic Florida — Jacksonville, Florida, United States
• The University of Chicago Medical Center — Chicago, Illinois, United States
• Mayo Clinic — Rochester, Minnesota, United States
• McGuire VA Medical Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.